Efficacy of Losartan in Hospitalized Patients With COVID-19-Induced Lung Injury: A Randomized Clinical Trial

SARS-CoV-2 viral entry may disrupt angiotensin II (AII) homeostasis, contributing to COVID-19 induced lung injury. AII type 1 receptor blockade mitigates lung injury in preclinical models, although data in humans with COVID-19 remain mixed. To test the efficacy of losartan to reduce lung injury in h...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA network open 2022-03, Vol.5 (3), p.e222735
Hauptverfasser:	Puskarich, Michael A, Ingraham, Nicholas E, Merck, Lisa H, Driver, Brian E, Wacker, David A, Black, Lauren Page, Jones, Alan E, Fletcher, Courtney V, South, Andrew M, Murray, Thomas A, Lewandowski, Christopher, Farhat, Joseph, Benoit, Justin L, Biros, Michelle H, Cherabuddi, Kartik, Chipman, Jeffrey G, Schacker, Timothy W, Guirgis, Faheem W, Voelker, Helen T, Koopmeiners, Joseph S, Tignanelli, Christopher J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Angiotensin II Type 1 Receptor Blockers - therapeutic use Clinical trials Coronaviruses COVID-19 COVID-19 - complications COVID-19 - diagnosis COVID-19 Drug Treatment Double-Blind Method Female Hospitalization Humans Infectious Diseases Losartan - therapeutic use Lung Injury - diagnosis Lung Injury - prevention & control Lung Injury - virology Male Middle Aged Online Only Organ Dysfunction Scores Original Investigation Respiratory Function Tests Severe acute respiratory syndrome coronavirus 2 United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!